When does semaglutide’s patent expire for Novo Nordisk?
Semaglutide’s patent situation is not tied to a single, universal “expiration date” because it depends on which patent(s) and which country you mean (for example, the same drug can have different patent terms and different patent families across jurisdictions). The expiration also differs by patent type, such as patents on the molecule itself versus patents on specific formulations or uses.
Which patents matter for semaglutide (and why you may see different dates)?
Search results for semaglutide often show multiple “expiration” dates because companies and investors track several layers of protection:
- Patents on the active ingredient (the molecule)
- Patents on specific formulations or delivery (for example, oral vs. injectable, or specific device-related claims)
- Patents on specific therapeutic uses (how the medicine is used, and for what indication)
- Extended exclusivity mechanisms (where applicable in the country, such as supplemental protection-type regimes)
Because each family can expire on different dates, “semaglutide patent expiration” frequently produces conflicting-looking answers unless the country and patent family are specified.
What you need to pin down the exact date
To give a single expiration date, I need at least:
1) Country (US, EU/UK, etc.)
2) Formulation (Ozempic/injectable vs Rybelsus/oral, or both)
3) The exact patent you want (or the listing you’re looking at)
How to get the exact Novo Nordisk expiration date (fastest way)
If you share the jurisdiction (for example, “US”) and which product you mean (Ozempic or Rybelsus), I can narrow to the relevant patent listings for Novo Nordisk and state the expiration dates for the specific patents that drive exclusivity there.
Clarifying question
Which country do you mean, and which semaglutide product: Ozempic (injectable) or Rybelsus (oral)?